Corneal molecular and cellular biology update for the refractive surgeon.
To review clinically relevant progress in understanding cellular and molecular interactions in the cornea that relate to refractive surgical outcomes in patients.



Recent published literature focused on femtosecond LASIK and surface ablation procedures, such as photorefractive keratectomy, was reviewed and correlated with clinical results of surgery.



The femtosecond laser has a direct necrotic effect on stromal keratocytes, resulting in the release of cellular components that are chemotactic to bone marrow-derived inflammatory cells. Developments of the femtosecond laser led to lower energy delivery to the stroma and altered laser ablation profiles that decrease epithelial damage during the side-cut, and have markedly improved femtosecond LASIK to the point that the overall early postoperative healing response is indistinguishable from microkeratome LASIK. New studies have directly demonstrated the importance of surface irregularity and resulting structural and functional defects in the epithelial basement membrane, in the generation and persistence of anterior stromal myofibroblasts and haze following surface ablation procedures. These defects augment penetration of epithelium-derived TGF-beta, which is a critical modulator of myofibroblast development in the stroma. Studies on the mechanism of action of mitomycin C treatment to prevent haze have confirmed that the most powerful effect is on stromal cell proliferation and, therefore, decreased population of the anterior stroma with myofibroblast progenitor cells. An undesirable long-term effect of mitomycin C is diminished anterior stromal keratocyte density due to diminished keratocyte re-population. This raises concerns regarding future corneal anomalies in treated corneas.



Basic research studies of refractive procedures provide important insights into the effects of wound healing on surgical outcomes.
Salomao
Marcella Q
MQ
The Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Wilson
Steven E
SE
D000477:Alkylating Agents / Q000008:administration & dosage; D017209:Apoptosis / Q000502:physiology; D003315:Cornea / Q000502:physiology*; D003318:Corneal Opacity / Q000517:prevention & control; D048988:Corneal Surgery, Laser; D006801:Humans; D054018:Lasers, Excimer / Q000627:therapeutic use; D016685:Mitomycin / Q000008:administration & dosage; D014945:Wound Healing / Q000502:physiology*
D000477:Alkylating Agents; D016685:Mitomycin